STOCK TITAN
  1. Home
  2. News
  3. BGNE

BeiGene, Ltd. American Depositary Shares - BGNE STOCK NEWS

Welcome to our dedicated page for BeiGene, Ltd. American Depositary Shares news (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene, Ltd. American Depositary Shares stock.

BeiGene, Ltd. (NASDAQ: BGNE) is a global biotechnology company specializing in the development and commercialization of innovative cancer treatments. With a robust portfolio focused on molecularly targeted and immuno-oncology drugs, BeiGene addresses crucial oncology targets such as Bruton's tyrosine kinase (BTK) and the immune checkpoint protein PD-1. The company’s notable products include tislelizumab, a PD-1 inhibitor, and zanubrutinib, a BTK inhibitor, which have shown promising results in treating various cancers. BeiGene’s latest achievements include FDA and European regulatory approvals, significant clinical trial successes, and partnerships aimed at expanding the reach of their therapies globally. The company operates across major markets, including China, the United States, and internationally, striving to make high-quality cancer treatments more accessible. BeiGene’s commitment to advancing global health equity is evident in its innovative drug pipeline and strategic collaborations.

News

BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®

Rhea-AI Summary
BeiGene's TEVIMBRA receives European Commission approval for the treatment of advanced or metastatic ESCC, while the FDA accepts the Biologics License Application for first-line treatment of ESCC. Positive results from clinical trials show survival benefit and potential for addressing unmet clinical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
News

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)

Rhea-AI Summary
BeiGene regains worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab) from Novartis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
News

BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Rhea-AI Summary
BeiGene to participate in Morgan Stanley conference on September 11th, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
conferences
News

BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results

Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) reported a total product revenue of $554 million in Q2 2023, an 82% increase from the prior-year period. Global sales of BRUKINSA totaled $308 million, marking a 139% increase from the previous year. The company also highlighted positive regulatory progress and development programs, including approvals and regulatory submissions for BRUKINSA and Tislelizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
earnings
-
News

BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC

Rhea-AI Summary
BeiGene receives positive opinion from CHMP for tislelizumab as monotherapy for esophageal squamous cell carcinoma after prior chemotherapy. The Phase 3 study showed a statistically significant and clinically meaningful survival benefit for tislelizumab compared to chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
News

BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication

Rhea-AI Summary
BeiGene's sNDA for BRUKINSA in combination with obinutuzumab for the treatment of relapsed or refractory follicular lymphoma has been accepted for review by the FDA. The target action date is set for the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
clinical trial
News

BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
partnership
-
News

BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
conferences
-
News

BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
none
News

BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
none

FAQ

What is the current stock price of BeiGene, Ltd. American Depositary Shares (BGNE)?

The current stock price of BeiGene, Ltd. American Depositary Shares (BGNE) is $189.23 as of November 15, 2024.

What is the market cap of BeiGene, Ltd. American Depositary Shares (BGNE)?

The market cap of BeiGene, Ltd. American Depositary Shares (BGNE) is approximately 19.9B.

What type of company is BeiGene, Ltd.?

BeiGene, Ltd. is a global biotechnology company focused on developing and commercializing innovative cancer treatments.

What are some of BeiGene’s notable products?

Some of BeiGene’s notable products include tislelizumab, a PD-1 inhibitor, and zanubrutinib, a BTK inhibitor.

What markets does BeiGene operate in?

BeiGene operates in major markets including China, the United States, and internationally.

What recent achievements has BeiGene accomplished?

Recent achievements include the FDA and European regulatory approvals for its cancer treatments, significant clinical trial successes, and strategic partnerships.

What are BeiGene’s primary focus areas in oncology?

BeiGene focuses on molecularly targeted and immuno-oncology drugs, addressing targets like BTK and the immune checkpoint protein PD-1.

How does BeiGene contribute to global health equity?

BeiGene contributes to global health equity by developing innovative cancer treatments and forming strategic collaborations to make these therapies more accessible.

What are the financial highlights for BeiGene's latest quarter?

For the latest quarter, BeiGene reported total revenues of $752 million with significant growth in BRUKINSA product sales in the U.S. and Europe.

What is the significance of BeiGene's drug zanubrutinib?

Zanubrutinib is a BTK inhibitor that has shown promising results in treating various cancers, leading to increased market share and regulatory approvals.

What strategic initiatives is BeiGene currently pursuing?

BeiGene is focusing on expanding its global presence, advancing its innovative drug pipeline, and enhancing collaborations to broaden the accessibility of its cancer treatments.

What impact has BeiGene made on cancer treatment accessibility?

BeiGene has made significant strides in making high-quality cancer treatments more accessible globally through innovative drug development and strategic partnerships.

Stock BGNE logo
BeiGene, Ltd. American Depositary Shares

Nasdaq:BGNE

BGNE Rankings

#548 Ranked by Market Cap
N/A Ranked by Dividends

BGNE Stock Data

19.88B
1.25B
19.48%
49.53%
1.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GRAND CAYMAN